Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/43886
Título: | Therapeutic l-asparaginase: upstream, downstream and beyond |
Autor(es): | Lopes, Andre Moreni Oliveira-Nascimento, Laura de Ribeiro, Artur Tairum Jr, Carlos Abrunhosa Breyer, Carlos Alexandre Oliveira, Marcos Antonio de Monteiro, Gisele Souza-Motta, Cristina Maria de Magalhães, Pérola de Oliveira Avendaño, Jorge Gonzalo Farías Cavaco-Paulo, Artur Mazzola, Priscila Gava Rangel-Yagui, Carlota de Oliveira Sette, Lara Durães Converti, Attilio Pessoa, Adalberto |
Palavras-chave: | Acute lymphoblastic leukemia antineoplastic activity biopharmaceutical l-asparaginase microbial l-asparaginase production |
Data: | 2017 |
Editora: | Informa Healthcare |
Revista: | Critical Reviews in Biotechnology |
Citação: | Lopes, Andre Moreni; Oliveira-Nascimento, Laura de; Ribeiro, Artur; Tairum Jr, Carlos Abrunhosa; Breyer, Carlos Alexandre; Oliveira, Marcos Antonio de; Monteiro, Gisele; Souza-Motta, Cristina Maria de; Magalhães, Pérola de Oliveira; Avendaño, Jorge Gonzalo Farías; Cavaco-Paulo, Artur; Mazzola, Priscila Gava; Rangel-Yagui, Carlota de Oliveira; Sette, Lara Durães; Converti, Attilio; Pessoa, Adalberto, Therapeutic l-asparaginase: upstream, downstream and beyond. Critical Reviews in Biotechnology, 37(1), 82-99, 2017 |
Resumo(s): | L-asparaginase (L-asparagine amino hydrolase, E.C.3.5.1.1) is an enzyme clinically accepted as an antitumor agent to treat acute lymphoblastic leukemia and lymphosarcoma. It catalyzes L-asparagine (Asn) hydrolysis to L-aspartate and ammonia, and Asn effective depletion results in cytotoxicity to leukemic cells. Microbial L-asparaginase (ASNase) production has attracted considerable attention owing to its cost effectiveness and eco-friendliness. The focus of this review is to provide a thorough review on microbial ASNase production, with special emphasis to microbial producers, conditions of enzyme production, protein engineering, downstream processes, biochemical characteristics, enzyme stability, bioavailability, toxicity and allergy potential. Some issues are also highlighted that will have to be addressed to achieve better therapeutic results and less side effects of ASNase use in cancer treatment: (a) search for new sources of this enzyme to increase its availability as a drug; (b) production of new ASNases with improved pharmacodynamics, pharmacokinetics and toxicological profiles, and (c) improvement of ASNase production by recombinant microorganisms. In this regard, rational protein engineering, directed mutagenesis, metabolic flux analysis and optimization of purification protocols are expected to play a paramount role in the near future. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/43886 |
DOI: | 10.3109/07388551.2015.1120705 |
ISSN: | 0738-8551 |
e-ISSN: | 1549-7801 |
Versão da editora: | http://informahealthcare.com/journal/bty |
Arbitragem científica: | yes |
Acesso: | Acesso restrito UMinho |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_30706_1.pdf Acesso restrito! | 1,78 MB | Adobe PDF | Ver/Abrir |